We've got the dirt on USDA’s final rule on plant biotech

May 15, 2020
It’s Friday, but we’ve got a jam-packed issue today: news on USDA’s new rule on food biotech, a new resource for learning about global COVID-19 collaborations, plus two must-watch videos. Here are just under 1,000 words, just under 5 minutes. P.S. Don’t miss the…
BIO

It’s Friday, but we’ve got a jam-packed issue today: news on USDA’s new rule on food biotech, a new resource for learning about global COVID-19 collaborations, plus two must-watch videos. Here are just under 1,000 words, just under 5 minutes.

P.S. Don’t miss the latest episode of the I AM BIO Podcast featuring Christi Shaw, CEO of Kite, Gilead’s cell therapy company, about CAR T and why “cancer doesn’t stop in the crisis.” Listen at www.bio.org/podcast or wherever you get your podcasts.

1 MINUTE WITH MICHELLE
CEO video.png

We've got the dirt on USDA’s final rule on plant biotech

As if it hasn’t already been a big news week, USDA finalized its long-awaited rule on plant biotechnology, and we published a new resource hub to help you understand it. Here’s the scoop.

The news: The U.S. Department of Agriculture (USDA) announced the final rule on modernizing plant biotech regulations—officially known as  the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (SECURE) rule—which USDA says will bring “plant biotechnology regulations into the 21st century by removing duplicative and antiquated processes.”

The rule says two kinds of plants do not require pre-market review: all new plants with crop-trait combos USDA has already approved, and plants with certain enumerated gene edits or with genetic changes that could have occurred through breeding.

And technology developers and plant breeders can self-determine whether they fall into one of the above categories—and if they do, they’re not required to notify the agency before commercializing the plant. 

BIO’s take: We’re still reviewing the details, but overall, we support the rule and believe it will accelerate the development of innovations that will improve resiliency and lives globally—especially in a time when the fragility of our food systems has been exposed through COVID-19. But, government and industry still have a lot of work to do to build an informed and trust-based dialogue about biotech in food and agriculture and its potential to help the planet, our food system, and human health. 

Dana’s Dialogue: Innovation flourishes when science and consumer values are aligned and complement one another. The U.S. government’s regulatory approach cannot exist in isolation. It should be supported by credible transparency measures. BIO understands that consumers want more information about what is in their food and whether their food is safe. Our members will be a driver of that endeavor. – Dana O’Brien, EVP of BIO’s Food and Agriculture Section

Read Dana’s Q&A about the rule.

And learn more about the new rule and how biotech can make food more plentiful, nutritious, and sustainable at our resource hub at www.bio.org/growing-trust-innovation.

Read more about BIO's Inclusive and Impactful Approach to Transparency. 

More Agriculture & Environment News: 

The New York Times: WTO chief quits suddenly, adding to global turmoil
“With Mr. Azevêdo’s departure, which caught officials in Geneva and Brussels by surprise, the organization will lose an advocate of open trade and international cooperation whose views clashed with President Trump’s preference for bilateral power politics.”

 
Twitter
 
LinkedIn
 
Facebook
 
BIOTECHNOLOGY: BEYOND IMAGINATION
Inovio Pharmaceuticals: Another Shot on Goal to Fight COVID-19
Inovio Pharmaceuticals: Another Shot on Goal Against COVID-19
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
 

Scientists at the Philadelphia-based Inovio Pharmaceuticals, a company that specializes in immunotherapy to treat and prevent infectious diseases, are using “immuno-ingenuity” to work on products that activate the immune system to help turn the body into its own medicine. 

With its innovative DNA vaccine candidate, INO-4800, the company specifically engineered DNA called plasmid to target COVID-19 at the cellular level, producing an antibody to help fight and defend the body from illness. 

Click here to watch and learn more about Inovio’s breakthrough vaccine candidate.


 

How the global biotech industry is united in the fight against COVID-19

We talk a lot about the unprecedented level of collaboration among biotech companies of all sizes right now. And a lot of this collaboration is happening at the global level. Today, we’re bringing you a new resource from our sister organization ICBA to help drive this effort.

BIO’s sister organization, the International Council of Biotech Associations (ICBA), the coalition of biotechnology trade associations around the world, launched a new destination for you to learn about global collaboration against the coronavirus. 

The goal is to elevate the contributions of the global biotech sector to the pandemic response by collating resources from ICBA member organizations around the world—including BIO’s new COVID-19 Tracker.

And these are groundbreaking collaborations that truly cross borders—like how BIO member Pfizer and Germany’s BioNTech are researching new kinds of immunotherapy treatments, or how BIO member Eli Lilly and Canada’s Abcellera have partnered to identify more than 500 human antibodies as possible candidates for a COVID-19 treatment.

Of note, the website highlights the policies necessary to support innovation and access to biotech products, including proposals on global supply chains, IP, free flow of scientific data, and regulations.

What they’re saying: “In these unprecedented times, global biotech companies large and small are coming together like never before to work on vaccines, therapeutics, and diagnostics. As the voice of the global sector, the International Council of Biotechnology Associations (ICBA) is supporting and driving this extraordinary collaboration to deliver a coordinated, transparent, robust, science-based, and most of all, global response,” says Steve Bates, Chair of ICBA and CEO of the UK BioIndustry Association. “We look forward to continuing to work with BIO, and all of our members around the world, in what is a defining moment for our industry.”

To learn more about what BIO’s doing in the COVID-19 fight, visit www.bio.org/coronavirus.

 

More Health Care News:

Bloomberg: Trump weighs made-in-U.S. order for vital drugs, devices
“The draft order is still in the preliminary stages and hasn’t gotten sign off from the president. It has reached other federal agencies for review and coordination, including the Pentagon and the Department of Health and Human Services.”

 
Twitter
 
LinkedIn
 
Facebook
 
BIO Beltway Report
GoodDayBIO
 
 

President Trump’s Friday: While visiting a medical supply distribution center in Pennsylvania yesterday, he announced the administration will expand the Strategic National Stockpile, “ensuring there's a 90-day supply of testing supplies and essential drugs,” reports POLITICO. It’s a busy Friday, as he’s expected to deliver remarks about vaccine development at noon ET, then receive the new United States Space Force flag, among other things. He’ll head to Camp David for the weekend.

What’s Happening on Capitol Hill: Former BARDA director Rick Bright made headlines yesterday with his four-hour testimony in front of the House Energy and Commerce Health Subcommittee. Today, the House is expected to vote on the $3 trillion stimulus package—which does not include any provisions for climate change or clean energy, which has lost 600,000 jobs during the pandemic, according to POLITICO Morning Energy.

 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
Twitter
 
LinkedIn
 
Facebook